3.38
-0.005(-0.15%)
Currency In USD
Previous Close | 3.38 |
Open | 3.29 |
Day High | 3.46 |
Day Low | 3.29 |
52-Week High | 19.3 |
52-Week Low | 1.08 |
Volume | 157,950 |
Average Volume | 4.02M |
Market Cap | 22.59M |
PE | -0.49 |
EPS | -6.82 |
Moving Average 50 Days | 3.51 |
Moving Average 200 Days | 2.16 |
Change | -0.01 |
If you invested $1000 in Sonnet BioTherapeutics Holdings, Inc. (SONN) 10 years ago, it would be worth $0 as of August 22, 2025 at a share price of $3.38. Whereas If you bought $1000 worth of Sonnet BioTherapeutics Holdings, Inc. (SONN) shares 5 years ago, it would be worth $0.18 as of August 22, 2025 at a share price of $3.38.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer
GlobeNewswire Inc.
Aug 04, 2025 12:40 PM GMT
Sonnet's lead product, SON-1010 (IL12-FHAB), is being evaluated in combination with atezolizumab (Tecentriq®) in patients with advanced platinum-resistant ovarian cancer (PROC) (SB221) Topline safety, cytokine, and efficacy data suggest a strong pote
Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy
GlobeNewswire Inc.
Jul 14, 2025 10:00 AM GMT
Combined company expected to become largest U.S.-based publicly listed company to hold HYPE in its treasuryPRINCETON, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics, Inc., (NASDAQ: SONN) (“Sonnet” or the “Company”) today announced t
Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit
GlobeNewswire Inc.
May 01, 2025 1:00 PM GMT
PRINCETON, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeting the tumor microenvironment (TME), today announc